Form DEFA14A Harmony Biosciences Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Oppenheimer on Harmony Biosciences (HRMY): 'we remain pleased with WAKIX's 4Q24 performance'
April 8, 2025 12:31 PM EDTOppenheimer analyst Francois Brisebois reiterated an Outperform rating and $61.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY)
The analyst comments "HRMY announced OLE data for ZYN002 in fragile X syndrome (FXS) that will be presented at AAN (4/8/25 podium presentation). We are pleased to see clinically... More
